Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC012F in Refractory Systemic Lupus Erythematosus
NCT05846347Phase 1Unknown
- Sponsor
- Zhejiang University
- Start
- May 2023
- Primary completion
- Oct 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC012 in systemic lupus erythematosus (SLE), sponsored by Zhejiang University. Primary endpoints: Dose Limiting Toxicity at 28 days and Adverse Events at 12 weeks. Status: unknown.
02
Drugs
GC012
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05846347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05846347.